William McVicar, President and CEO of Flex Pharma Inc (NASDAQ: FLKS) tells Proactive Investors at the BIO CEO Conference in New York, that Flex Pharma is shaping up to be an exciting year ahead.
McVicar says Flex Pharma will have clinical trials reading out in the Q1 as well as in Q3 in ALS, multiple sclerosis, and Charcot-Marie-Tooth disease. Flex Pharma will report Q4 and full year 2017 results on March 7, 2018.
Meet Scancell Holdings Plc, Advanced Blast & Ballistic Systems Ltd and TokenCommunities Plc at our event, London, 08 March 2018.Register here >>